KR101216655B1 - Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암환자에 대한 그들의 용도 - Google Patents

Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암환자에 대한 그들의 용도 Download PDF

Info

Publication number
KR101216655B1
KR101216655B1 KR1020067012186A KR20067012186A KR101216655B1 KR 101216655 B1 KR101216655 B1 KR 101216655B1 KR 1020067012186 A KR1020067012186 A KR 1020067012186A KR 20067012186 A KR20067012186 A KR 20067012186A KR 101216655 B1 KR101216655 B1 KR 101216655B1
Authority
KR
South Korea
Prior art keywords
peptide
hla
bcl
delete delete
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067012186A
Other languages
English (en)
Korean (ko)
Other versions
KR20060132622A (ko
Inventor
에이빈드 펄 토르 스탈텐
매즈 할드 앤더슨
Original Assignee
수르벡 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수르벡 에이피에스 filed Critical 수르벡 에이피에스
Publication of KR20060132622A publication Critical patent/KR20060132622A/ko
Application granted granted Critical
Publication of KR101216655B1 publication Critical patent/KR101216655B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067012186A 2003-11-19 2004-11-18 Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암환자에 대한 그들의 용도 Expired - Lifetime KR101216655B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52311903P 2003-11-19 2003-11-19
US60/523,119 2003-11-19
DKPA200301716 2003-11-19
DKPA200301716 2003-11-19
PCT/DK2004/000799 WO2005049073A2 (en) 2003-11-19 2004-11-18 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020127016885A Division KR101284237B1 (ko) 2003-11-19 2004-11-18 Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암 환자에 대한 그들의 용도

Publications (2)

Publication Number Publication Date
KR20060132622A KR20060132622A (ko) 2006-12-21
KR101216655B1 true KR101216655B1 (ko) 2013-01-02

Family

ID=39149116

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020067012186A Expired - Lifetime KR101216655B1 (ko) 2003-11-19 2004-11-18 Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암환자에 대한 그들의 용도
KR1020127016885A Expired - Lifetime KR101284237B1 (ko) 2003-11-19 2004-11-18 Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암 환자에 대한 그들의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127016885A Expired - Lifetime KR101284237B1 (ko) 2003-11-19 2004-11-18 Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암 환자에 대한 그들의 용도

Country Status (17)

Country Link
US (1) US7842294B2 (enExample)
EP (2) EP1691824B1 (enExample)
JP (2) JP4926714B2 (enExample)
KR (2) KR101216655B1 (enExample)
CN (1) CN1921878B (enExample)
AT (1) ATE424842T1 (enExample)
AU (1) AU2004290866B2 (enExample)
CA (1) CA2546794C (enExample)
DE (1) DE602004019965D1 (enExample)
DK (2) DK1691824T3 (enExample)
ES (2) ES2323588T3 (enExample)
MX (1) MXPA06005738A (enExample)
PL (2) PL1691824T3 (enExample)
PT (1) PT1691824E (enExample)
RU (1) RU2367468C2 (enExample)
WO (1) WO2005049073A2 (enExample)
ZA (1) ZA200604866B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
PT2359841E (pt) * 2003-01-30 2015-02-10 Survac Aps Péptidos derivados de survivina e a sua utilização
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
CA2584990A1 (en) * 2004-10-19 2006-04-27 Massachusetts Institute Of Technology Virus scaffold for self-assembled, flexible and light lithium battery
AU2011203535B2 (en) * 2005-02-04 2012-10-11 Survac Aps Survivin peptide vaccine
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
EP1934250A2 (en) * 2005-09-09 2008-06-25 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Methods and compositions for inhibiting cell death or enhancing cell proliferation
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2009106073A2 (en) * 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
ES2820873T3 (es) 2008-05-16 2021-04-22 Taiga Biotechnologies Inc Anticuerpos y su procesos de preparación
EP2313516A4 (en) * 2008-07-16 2012-04-04 Burnham Inst Medical Research COMPOSITIONS AND METHODS FOR MODULATING THE NOD LIKE RECEPTOR ACTIVITY AND THEIR USE
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
ES2681478T3 (es) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
JP2012505918A (ja) * 2008-10-17 2012-03-08 ユニバーシティー オブ マイアミ 腫瘍ワクチン
US20120251509A1 (en) * 2009-10-22 2012-10-04 Waldman Scott A Cell-based anti-cancer compositions and methods of making and using the same
CN105601727B (zh) * 2010-03-11 2020-01-10 肿瘤疗法科学股份有限公司 Hjurp肽及包含它们的疫苗
AU2011293522B2 (en) * 2010-08-24 2015-03-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
SI3536334T1 (sl) 2012-05-16 2021-11-30 Stemline Therapeutics Inc. Cepiva proti raku, ki ciljajo na rakave matične celice
CA3133302A1 (en) * 2012-07-20 2014-01-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
EP2961419A4 (en) * 2013-02-26 2016-12-21 Rongfu Wang PHF20 AND JMJD3 COMPOSITIONS AND METHOD FOR USE IN CANCER IMMUNOTHERAPY
US20160010058A1 (en) * 2013-03-01 2016-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of producing enriched populations of tumor-reactive t cells from tumor
US9704181B2 (en) * 2014-05-06 2017-07-11 International Business Machines Corporation Real-time social group based bidding system
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
CR20210128A (es) 2017-01-27 2021-04-26 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cancer (divisional exp. 2019-388)
US10738100B2 (en) 2017-01-27 2020-08-11 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
TWI796314B (zh) * 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
AU2019334437A1 (en) 2018-09-04 2021-03-18 Treos Bio Limited Peptide vaccines
EP3898666A2 (en) 2018-12-17 2021-10-27 Immudex ApS Panel comprising borrelia mhc multimers
AU2020272664A1 (en) 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
AU2020274117A1 (en) 2019-05-14 2021-12-02 Taiga Biotechnologies, Inc. Compositions and methods for treating T cell exhaustion
CN113355432A (zh) * 2021-05-12 2021-09-07 甘肃农业大学 Bmf作为细胞凋亡标志物的应用
WO2022245249A1 (ru) * 2021-05-17 2022-11-24 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Пептидные соединения для индукции апоптоза в опухолевой клетке

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856171A (en) 1993-08-26 1999-01-05 Washington University Cell death regulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
FI950887A7 (fi) 1992-08-31 1995-02-27 Ludwig Inst For Cancer Res Ltd MAGE-3-geenistä peräisin oleva ja HLA-A1-proteiinin tarjoama eristetty nonapeptidi ja sen käytöt
US5470955A (en) * 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5789201A (en) * 1996-02-23 1998-08-04 Cocensys, Inc. Genes coding for bcl-y a bcl-2 homologue
AU736587B2 (en) 1996-11-20 2001-08-02 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
WO1998058541A1 (en) * 1997-06-24 1998-12-30 Dana-Farber Cancer Institute, Inc. Modulation of apoptosis
AU3471200A (en) * 1999-11-16 2001-05-30 Dartmouth College Mcl-1 gene regulatory elements and a pro-apoptotic mcl-1 variant
AU2578401A (en) 1999-12-14 2001-06-25 Burnham Institute, The Bcl-g polypeptides, encoding nucleic acids and methods of use
AU2001271426A1 (en) * 2000-07-17 2002-01-30 Washington University Modulation of apoptosis
WO2002072627A2 (en) 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1618130B1 (en) 2003-04-11 2013-03-27 Survac ApS Therapeutic cancer vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856171A (en) 1993-08-26 1999-01-05 Washington University Cell death regulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blood Vol.105(2):728-734 (2005. 1. 15.)
Journal of Experimental Medicine Vol.197(11):1489-1500 (2003. 6. 2.)*

Also Published As

Publication number Publication date
ATE424842T1 (de) 2009-03-15
US20080050396A1 (en) 2008-02-28
ES2323588T3 (es) 2009-07-21
RU2006121466A (ru) 2007-12-27
WO2005049073A2 (en) 2005-06-02
RU2367468C2 (ru) 2009-09-20
EP1691824B1 (en) 2009-03-11
CA2546794C (en) 2013-09-17
JP2007511547A (ja) 2007-05-10
CA2546794A1 (en) 2005-06-02
US7842294B2 (en) 2010-11-30
JP2011246496A (ja) 2011-12-08
ES2436429T3 (es) 2014-01-02
DK2087904T3 (da) 2013-12-02
AU2004290866B2 (en) 2010-09-02
DE602004019965D1 (de) 2009-04-23
JP5502823B2 (ja) 2014-05-28
CN1921878A (zh) 2007-02-28
JP4926714B2 (ja) 2012-05-09
EP2087904A1 (en) 2009-08-12
HK1101131A1 (en) 2007-10-12
PL1691824T3 (pl) 2009-08-31
EP1691824A2 (en) 2006-08-23
MXPA06005738A (es) 2006-12-14
PL2087904T3 (pl) 2014-01-31
CN1921878B (zh) 2012-04-25
AU2004290866A1 (en) 2005-06-02
WO2005049073A3 (en) 2006-01-05
KR101284237B1 (ko) 2013-07-09
DK1691824T3 (da) 2009-07-06
EP2087904B1 (en) 2013-08-28
KR20060132622A (ko) 2006-12-21
ZA200604866B (en) 2008-05-28
KR20130026527A (ko) 2013-03-13
PT1691824E (pt) 2009-05-28

Similar Documents

Publication Publication Date Title
KR101216655B1 (ko) Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암환자에 대한 그들의 용도
AU2022200745B2 (en) Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
KR20170003976A (ko) 급성 골수성 백혈병(aml)과 같은 여러 혈액 종양에 대한 신규 면역요법
HK40026447A (en) Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
HK1101131B (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060619

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20091118

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110629

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120428

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20120628

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20121023

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20121221

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20121224

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20151118

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20151118

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20161122

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20161122

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20171120

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20171120

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20181129

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20181129

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20191202

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20191202

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20201201

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20211201

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20221121

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20231120

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20250518

Termination category: Expiration of duration